Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152254 · ClinicalTrials.gov registry record · Phase 2
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)
A Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 1,362
- Enrollment target
- 1
- Study location
NCT02152254 is a Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,362 participants, above the 248-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (449% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02152254, a Phase 2 study of Metastatic Malignant Neoplasm and Recurrent Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,362 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized clinical trial studies how molecular profiling and targeted therapy work in treating patients with cancer that has spread to other places in the body compared to standard treatment. Information about genetic differences in a patient's tumor can be used to choose treatment that may target the tumor. It is not yet validated whether selecting treatment after studying the genetic changes that are associated with cancer in a patient's tumor is a better way to treat patients with metastatic cancer compared to therapy not based on studying the genetic changes that are associated with cancer.
Conditions Studied
Interventions
- DRUG Targeted Therapy Based on Molecular Profiling
- DRUG Standard-of-Care Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,362 participants |
| Start Date | 2014-05-13 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152254
The ClinicalTrials.gov registry entry for NCT02152254 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,362 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 248-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (449% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Targeted Therapy Based on Molecular Profiling is the first listed.
NCT02152254 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02152254 about?
NCT02152254 is a clinical study titled "Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)". This randomized clinical trial studies how molecular profiling and targeted therapy work in treating patients with cancer that has spread to other places in the body compared to standard treatment. Information about genetic differences in a patient's tumor can be used to choose treatment that may ta...
What is the current status of trial NCT02152254?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,362 participants. The study started on 2014-05-13. Estimated completion is 2030-12-31.
What conditions does trial NCT02152254 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm.
What interventions are being tested in trial NCT02152254?
The interventions under investigation include: Targeted Therapy Based on Molecular Profiling (DRUG), Standard-of-Care Therapy (DRUG).
Who is sponsoring clinical trial NCT02152254?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02152254 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer
RECRUITING · Phase 2
-
Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.